Of these, 11 had negative survival outcomes, including lung cancer (4), breast cancer (2), liposarcoma (1), prostate cancer (1), leukemia (1), colon cancer (1), and glioma (1), which is consistent with the positive contribution of PKM2 to cancer metabolism. The gene discussed is PKM; the disease is lung carcinoma.